benzyl N-[5-(3-nitrophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate | 215511-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: benzyl N-[5-(3-nitrophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate
• CAS: 215511-62-9
• 化学式: C₂₃H₁₈N₄O₅
• 分子量: 430.42
• InChiKey: IPYOIDVGXHIQEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  benzyl N-[5-(3-nitrophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate 在 palladium on activated charcoal 吡啶 、 甲酸 、 氢溴酸 、 乙酸酐 、 potassium carbonate 、 三乙胺 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 5.17h， 生成 tert-butyl 2-[5-(3-formamidophenyl)-2-oxo-3-(quinolin-8-ylsulfonylamino)-3H-1,4-benzodiazepin-1-yl]acetate
  参考文献：
  名称：

  Design, syntheses, and activity of new 3-[(sulfonylaryl)-amino]-1,4-benzodiazepin-2-one derivatives as α-thrombin inhibitors

  摘要：

  Thrombin plays a central role in thrombosis. Because of the medical need for novel antithrombotic drugs, a search for structurally novel thrombin inhibitors was undertaken. In the absence of a crystal structure, a class was designed based on a modeling approach which involved placing the essential functional groups of the thrombin antagonist MD-805 [1] (Argatroban) into the benzodiazepine nucleus. The best superposition was obtained with a 1,4-benzodiazepin-2-one containing a 1,2,3,4-tetrahydro quinolylsulfonyl moiety in the 3-position, a guanidino-phenyl at the 5-position, and Ni-substituted with an acetic acid. Synthesis of these molecules provided compounds with an inhibitory activity with K-i in the range of 40-1000 mu M. A report on the crystal structure of thrombin*hirudin(55-65)*MD-805 complex [2] suggested subsequent molecular modeling investigations to rationalize the pharmacological results. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80048-2
• 作为产物：
  描述：

  benzyl N-[2-[2-(3-nitrobenzoyl)anilino]-2-oxo-1-propan-2-ylsulfanylethyl]carbamate 在 ammonium acetate 、 氨 、 mercury dichloride 作用下， 以 四氢呋喃 、 溶剂黄146 为溶剂， 反应 3.0h， 生成 benzyl N-[5-(3-nitrophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate
  参考文献：
  名称：

  Design, syntheses, and activity of new 3-[(sulfonylaryl)-amino]-1,4-benzodiazepin-2-one derivatives as α-thrombin inhibitors

  摘要：

  Thrombin plays a central role in thrombosis. Because of the medical need for novel antithrombotic drugs, a search for structurally novel thrombin inhibitors was undertaken. In the absence of a crystal structure, a class was designed based on a modeling approach which involved placing the essential functional groups of the thrombin antagonist MD-805 [1] (Argatroban) into the benzodiazepine nucleus. The best superposition was obtained with a 1,4-benzodiazepin-2-one containing a 1,2,3,4-tetrahydro quinolylsulfonyl moiety in the 3-position, a guanidino-phenyl at the 5-position, and Ni-substituted with an acetic acid. Synthesis of these molecules provided compounds with an inhibitory activity with K-i in the range of 40-1000 mu M. A report on the crystal structure of thrombin*hirudin(55-65)*MD-805 complex [2] suggested subsequent molecular modeling investigations to rationalize the pharmacological results. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80048-2

文献信息

• Design, syntheses, and activity of new 3-[(sulfonylaryl)-amino]-1,4-benzodiazepin-2-one derivatives as α-thrombin inhibitors
  作者：Daniel Dumas、Gérard Leclerc、John J. Baldwin、S. Dale Lewis、Mark Murcko、Adel M. Naylor-Olsen

  DOI：10.1016/s0223-5234(98)80048-2

  日期：1998.6

  Thrombin plays a central role in thrombosis. Because of the medical need for novel antithrombotic drugs, a search for structurally novel thrombin inhibitors was undertaken. In the absence of a crystal structure, a class was designed based on a modeling approach which involved placing the essential functional groups of the thrombin antagonist MD-805 [1] (Argatroban) into the benzodiazepine nucleus. The best superposition was obtained with a 1,4-benzodiazepin-2-one containing a 1,2,3,4-tetrahydro quinolylsulfonyl moiety in the 3-position, a guanidino-phenyl at the 5-position, and Ni-substituted with an acetic acid. Synthesis of these molecules provided compounds with an inhibitory activity with K-i in the range of 40-1000 mu M. A report on the crystal structure of thrombin*hirudin(55-65)*MD-805 complex [2] suggested subsequent molecular modeling investigations to rationalize the pharmacological results. (C) Elsevier, Paris.